US Bancorp DE Boosts Holdings in Insulet Co. (NASDAQ:PODD)

US Bancorp DE boosted its position in shares of Insulet Co. (NASDAQ:PODD) by 1.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,347 shares of the medical instruments supplier’s stock after buying an additional 227 shares during the quarter. US Bancorp DE’s holdings in Insulet were worth $3,339,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Wedmont Private Capital boosted its stake in Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 48 shares during the period. Blue Trust Inc. lifted its position in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after purchasing an additional 66 shares during the last quarter. Greenleaf Trust lifted its position in shares of Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock worth $415,000 after purchasing an additional 72 shares during the last quarter. Finally, UMB Bank n.a. lifted its position in shares of Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PODD shares. Barclays lifted their target price on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Canaccord Genuity Group lifted their target price on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. UBS Group lifted their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Citigroup lifted their price objective on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Finally, Piper Sandler lifted their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $242.29.

Insulet Stock Performance

Shares of Insulet stock opened at $241.32 on Wednesday. The company has a market capitalization of $16.92 billion, a PE ratio of 43.17, a P/E/G ratio of 4.40 and a beta of 1.22. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. The company has a 50-day simple moving average of $228.23 and a two-hundred day simple moving average of $202.16. Insulet Co. has a one year low of $151.56 and a one year high of $243.98.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The firm had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 earnings per share. Research analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.